Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
NCT05723978 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 520
Last updated 2023-02-13
Summary
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present.
The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.
Conditions
- Carcinoma, Pancreatic Ductal
Interventions
- PROCEDURE
-
Selective extended dissection of pancreaticoduodenectomy
An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
Sponsors & Collaborators
-
Tianjin Medical University Cancer Institute and Hospital
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-01-01
- Primary Completion
- 2022-07-01
- Completion
- 2022-12-01
Countries
- China
Study Locations
More Related Trials
-
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
NCT04737551 ·Status: UNKNOWN
-
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
NCT04835064 ·Status: UNKNOWN ·Phase: PHASE3
-
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
NCT06873178 ·Status: ACTIVE_NOT_RECRUITING
-
Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma Patients
NCT06378853 ·Status: COMPLETED
-
Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients
NCT06147154 ·Status: COMPLETED
-
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
NCT03498326 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
NCT05888129 ·Status: COMPLETED
-
Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center
NCT05141656 ·Status: UNKNOWN
-
Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?
NCT02787187 ·Status: COMPLETED ·Phase: NA
-
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
NCT02928081 ·Status: UNKNOWN ·Phase: NA
-
Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma.
NCT04115527 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy
NCT03398291 ·Status: UNKNOWN ·Phase: PHASE3
-
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
NCT05356039 ·Status: RECRUITING
-
Pancreatic Cancer and Diabetes Mellitus
NCT06585072 ·Status: RECRUITING
-
The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer
NCT05438797 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Early Recurrence After Surgery for Pancreatic Cancer
NCT07241676 ·Status: ENROLLING_BY_INVITATION
-
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma
NCT02978547 ·Status: UNKNOWN ·Phase: PHASE2
-
Translational Research on Locally Advanced Pancreatic Adenocarcinoma
NCT03009253 ·Status: UNKNOWN ·Phase: NA
-
Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
NCT02685228 ·Status: UNKNOWN ·Phase: NA
-
Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery
NCT05830019 ·Status: UNKNOWN ·Phase: NA
-
A Study of Extended Total Mesopancreas Excision(eTME) for Pancreatic Head Adenocarcinoma.
NCT04147403 ·Status: UNKNOWN
-
Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes
NCT07272109 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Effects of Different Methods of PDAC Specimen Acquisition on Primary Cell Culture and Application
NCT04797676 ·Status: UNKNOWN
-
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
NCT05634564 ·Status: UNKNOWN ·Phase: PHASE2
-
Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma
NCT05248750 ·Status: RECRUITING